Advanced Enzyme Technologies announced its audited financial results for the fourth quarter and financial year ended March 31, 2026, reporting a robust consolidated performance. Net profit for FY26 rose 30% to ₹1,736 million compared to ₹1,340 million in the previous year, while revenue from operations increased by 17% to ₹7,458 million from ₹6,369 million in FY25. The board recommended a final dividend of ₹1.35 per equity share for the financial year ended March 31, 2026, subject to shareholder approval. Alongside the results, the company shared its strategic growth plans for FY27, focusing on B2C expansion and geographic diversification.

Consolidated Financial Performance

For the fourth quarter of FY26, revenue from operations grew by 22% year-on-year to ₹2,034 million, up from ₹1,672 million in Q4 FY25. Net profit for the quarter surged by 69% to ₹453 million from ₹267 million in the corresponding period of the previous year. EBITDA for Q4 FY26 stood at ₹632 million, a 39% increase from ₹456 million in Q4 FY25, with the EBITDA margin expanding to 31% from 27%. The following table summarises the key consolidated financial metrics for the quarter and full year:

Segment and Geographical Performance

The Human Nutrition segment was the primary growth driver, contributing 63% to total revenue in Q4 FY26. It grew by 24% year-on-year to ₹1,281 million, driven by increased activities in the Pharma/API and Bio-catalysis businesses. For the full year FY26, the segment grew by 15% to ₹4,674 million. The Animal Nutrition segment grew by 19% in Q4 FY26 to ₹250 million and by 25% for the full year to ₹946 million. The Bio-Processing segment reported a 17% growth in Q4 FY26 to ₹324 million, while the Specialized Manufacturing segment grew by 17% to ₹180 million.

Geographically, India remained the largest market, contributing 52% to Q4 FY26 revenue with ₹1,061 million, representing a 51% year-on-year growth. Domestic sales accounted for 50% of the total revenue for FY26. International sales stood at ₹973 million in Q4 FY26, with the Americas and Europe seeing declines of 11% and 7% respectively, while Asia (ex-India) grew by 38%.

FY27 Growth Strategy and Operational Highlights

Advanced Enzyme Technologies has outlined a focused growth strategy for FY27 centred on expanding its B2C presence and strengthening its international sales infrastructure. The company launched its own nutraceutical brand, Wellfa, in India to drive B2C growth within the Human Nutrition segment. In the Animal Nutrition segment, the company plans to expand its sales team across the USA, MENA, and Asian regions to capture a larger share of international markets. The company is also conducting trials to develop new Animal Nutrition products and noted progress in Bio Catalysis for API manufacturers, with several products in advanced plant-level trials. Additionally, Advanced Enzyme Technologies remains committed to exploring strategic inorganic acquisition opportunities to enhance its global footprint.

Advanced enzyme tech has filed its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The certificate submission demonstrates the company's adherence to mandatory regulatory requirements governing securities dematerialisation processes.

Regulatory Compliance Details

The certificate was submitted under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. Company Secretary and Head-Legal Sanjay Basantani signed the submission letter dated April 10, 2026, forwarding the certificate to both BSE Limited and National Stock Exchange of India Limited.

Registrar and Transfer Agent Confirmation

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, serves as the company's Registrar and Transfer Agents. The agency provided the confirmation certificate dated April 3, 2026, signed by Sr. Vice President-Corporate Registry Ashok Shetty.

The certificate confirms that securities received from depository participants for dematerialisation during the quarter were properly processed within prescribed timelines. MUFG Intime confirmed that all security certificates received for dematerialisation were appropriately verified, mutilated, and cancelled after due verification by depository participants.

Dematerialisation Process Compliance

The confirmation certificate validates several key compliance aspects:

• Securities received for dematerialisation were confirmed or rejected to depositories within required timeframes
• All securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates were properly mutilated and cancelled after verification
• Depository names were substituted in the register of members as registered owners

This quarterly filing represents standard regulatory compliance for listed companies, ensuring proper handling of securities dematerialisation processes and maintaining transparency in depository participant operations.